GKT137831: Dual Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary: GKT137831 is a highly selective dual inhibitor of NADPH oxidase isoforms Nox1 and Nox4, achieving Ki values of 140 nM and 110 nM, respectively, under in vitro conditions (APExBIO, product data). The compound attenuates reactive oxygen species (ROS) production, modulates Akt/mTOR and NF-κB signaling, and downregulates pro-fibrotic markers such as TGF-β1 (Laleu 2010, DOI). In vivo, oral administration (30–60 mg/kg/day) reduces chronic hypoxia-induced pulmonary vascular remodeling, right ventricular hypertrophy, and liver fibrosis in murine models (Aoyama 2012, DOI). GKT137831 is provided by APExBIO and is widely used in disease models where oxidative stress is implicated (B4763 kit). Its robust selectivity and workflow compatibility make it indispensable for advanced redox research (contrast: advanced oxidative stress investigations).

Biological Rationale

NADPH oxidases (NOX enzymes) are primary sources of cellular ROS. Nox1 and Nox4 isoforms are implicated in pathological oxidative stress, driving processes such as fibrosis, vascular remodeling, and atherosclerosis (Laleu 2010, DOI). Excess ROS activates redox-sensitive signaling cascades, including Akt/mTOR and NF-κB, leading to cell proliferation, inflammation, and tissue remodeling. Targeting dual Nox1/Nox4 activity enables precise modulation of these pathways and downstream events. GKT137831, developed by APExBIO, selectively inhibits both isoforms, allowing dissection of NOX-derived ROS in complex disease models (product page). This article extends prior discussions by detailing benchmark data and specifying workflow integration, expanding on prior overviews (contrast: translational versatility).

Mechanism of Action of GKT137831

GKT137831 is a small molecule inhibitor that targets the catalytic core of Nox1 and Nox4. Inhibition occurs at nanomolar concentrations (Ki: Nox1 = 140 nM, Nox4 = 110 nM), preventing electron transfer from NADPH to molecular oxygen and thus blocking superoxide and hydrogen peroxide generation (Laleu 2010, DOI). Reduced ROS leads to diminished activation of redox-responsive signaling proteins, such as Akt and NF-κB. In endothelial and smooth muscle cell cultures, GKT137831 suppresses hypoxia-induced H2O2 release and cell proliferation (Li 2019, DOI). The compound also modulates expression of TGF-β1 and PPARγ, key regulators of fibrosis and metabolic homeostasis. The dual Nox1/Nox4 inhibition profile distinguishes GKT137831 from isoform-specific inhibitors, enabling comprehensive ROS modulation in multifactorial disease states.

Evidence & Benchmarks

• GKT137831 inhibits Nox1 (Ki = 140 nM) and Nox4 (Ki = 110 nM) in vitro (Laleu 2010, DOI).
• In HPAECs and HPASMCs, 10 μM GKT137831 reduces hypoxia-induced H2O2 by >60% after 24 hours (Li 2019, DOI).
• Oral dosing (30–60 mg/kg/day) attenuates right ventricular hypertrophy and pulmonary vascular remodeling in mouse models (Aoyama 2012, DOI).
• GKT137831 lowers TGF-β1 expression and fibrotic deposition in liver tissue (Aoyama 2012, DOI).
• Reduces diabetes-accelerated atherosclerosis in ApoE-/- mice (Gray 2016, DOI).
• Demonstrates solubility ≥39.5 mg/mL in DMSO, ≥2.96 mg/mL in ethanol (APExBIO, product data).
• Clinical studies have evaluated safety and target engagement in fibrotic disease (Sedej 2019, NCT02010242).

This evidence expands on prior reviews by enumerating quantitative benchmarks in cellular and animal models (contrast: future-oriented strategy).

Applications, Limits & Misconceptions

Applications: GKT137831 is used to dissect the roles of Nox1/Nox4-derived ROS in models of pulmonary hypertension, liver fibrosis, and diabetes-accelerated atherosclerosis. It is also applied in studies of cellular redox signaling, including ferroptosis and membrane biology (Yang et al., Sci Adv 2025). The compound enables mechanistic studies on Akt/mTOR and NF-κB pathway modulation, and its selectivity reduces confounding off-target effects.

Common Pitfalls or Misconceptions

• GKT137831 does not inhibit all NOX isoforms; efficacy is limited to Nox1/Nox4 and is negligible for Nox2, Nox3, or Nox5 (Laleu 2010, DOI).
• The compound is insoluble in water, requiring DMSO or ethanol for stock preparation (APExBIO, product page).
• Long-term storage of solutions (>1 week) is not recommended due to potential degradation (APExBIO).
• Observed effects at concentrations >20 μM may reflect off-target activity or cytotoxicity; optimal experimental window is 0.1–20 μM (APExBIO).
• In vivo efficacy may vary by species, disease context, and dosing schedule—validation in the intended model is essential.

Workflow Integration & Parameters

GKT137831 is typically used at 0.1–20 μM in cell culture, with incubation times of 24 hours. For in vivo work, recommended oral doses are 30–60 mg/kg/day in mouse models, with vehicles such as 0.5% methylcellulose. Stock solutions should be prepared in DMSO at ≥39.5 mg/mL, stored at -20°C, and diluted immediately before use. APExBIO provides comprehensive technical documentation and batch consistency for the B4763 kit (product details). For protocol optimization and troubleshooting, consult advanced reviews (contrast: experimental selectivity).

Conclusion & Outlook

GKT137831 is a benchmark dual Nox1/Nox4 inhibitor that enables rigorous investigation of oxidative stress mechanisms in both basic and translational settings. Its high selectivity, robust in vitro and in vivo performance, and compatibility with redox signaling studies make it a pivotal tool in fibrosis, vascular biology, and metabolic disease research. Future directions include expanded clinical evaluation and integration with emerging redox modulation strategies (Yang et al., Sci Adv 2025).